Received Jun 1, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| TDAP | TDAP (BOOSTRIX) | GLAXOSMITHKLINE BIOLOGICALS | UNK | 5N9L9 | — |
Boostrix administration to a 28-month-old patient; This non-serious case was reported by a other health professional via call center representative and described the occurrence of inappropriate age at vaccine administration in a 28-month-old male patient who received DTPa (Reduced antigen) (Boostrix) suspension for injection in pre-filled syringe (batch number 5N9L9 with expiry date 28-NOV-2027) for prophylaxis. On 06-MAY-2026, the patient received Boostrix. On 06-MAY-2026, an unknown time after receiving Boostrix, the patient experienced inappropriate age at vaccine administration (Verbatim: Boostrix administration to a 28-month-old patient).The outcome of the inappropriate age at vaccine administration was not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date:27-MAY-2026 Healthcare provider wanted to know if there are side effects known on the administration of Boostrix to a 28-month-old. The intention for this administration was unknown by the provider, mentioning that it could have been for catching up, but with no certainty on it.